

## Results of General Meeting

**Emyria Limited (ASX: EMD)** (Emyria or the Company), a clinical stage biotech, advises that a General Meeting of shareholders was held today, 25 January 2023. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

### Poll Results

		For		Against		Abstain
Resolutions		Number	%	Number	%	Number
1	Ratification of prior issue of Tattarang Shares under Listing Rule 7.1A	105,994,009	99.93	78,497	0.07	216,250
2	Ratification of prior issue of Tattarang Options under Listing Rule 7.1	106,892,241	99.87	138,497	0.13	156,250
3(a)	Approval of Issue of Tranche 2 Director Securities – Dr Stewart Washer	59,800,538	99.7	182,343	0.30	21,582,064
3(b)	Approval of Issue of Tranche 2 Director Securities – Dr Karen Smith	109,126,137	99.83	182,343	0.17	656,465
3(c)	Approval of Issue of Tranche 2 Director Securities – Dr Alistair Vickery	109,126,137	99.83	182,343	0.17	656,465
3(d)	Approval of Issue of Tranche 2 Director Securities – Mr Matthew Callahan	89,526,137	99.80	182,343	0.20	20,256,465
3(e)	Approval of Issue of Tranche 2 Director Securities – Dr Michael Winlo	109,186,137	99.89	122,343	0.11	656,465
4	Approval of issue of Lead Manager Options	108,960,198	99.88	348,497	0.32	656,250

## Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	<b>Ratification of prior issue of Tattarang Shares under Listing Rule 7.1A</b>	98,215,450	78,497	51,000	216,250
2	<b>Ratification of prior issue of Tattarang Options under Listing Rule 7.1</b>	99,113,862	138,497	51,000	156,250
3(a)	<b>Approval of Issue of Tranche 2 Director Securities – Dr Stewart Washer</b>	53,357,578	182,343	41,000	20,256,465
3(b)	<b>Approval of Issue of Tranche 2 Director Securities – Dr Karen Smith</b>	101,357,578	182,343	41,000	656,465
3(c)	<b>Approval of Issue of Tranche 2 Director Securities – Dr Alistair Vickery</b>	101,357,578	182,343	41,000	656,465
3(d)	<b>Approval of Issue of Tranche 2 Director Securities – Mr Matthew Callahan</b>	81,757,578	182,343	41,000	20,256,465
3(e)	<b>Approval of Issue of Tranche 2 Director Securities – Dr Michael Winlo</b>	101,417,578	122,343	41,000	656,465
4	<b>Approval of issue of Lead Manager Options</b>	101,191,639	348,497	41,000	656,250

Release authorised by:  
Simon Robertson  
Company Secretary

## FOR FURTHER INFORMATION

**Dr. Michael Winlo**  
**Managing Director**  
**+61 (0) 8 6559 2800**  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Lexi O'Halloran**  
**Investor Relations**  
**+61 (0) 404 577 076**  
[investors@emyria.com](mailto:investors@emyria.com)

**Andrew Williams**  
**Media Relations**  
**+61 (0) 416 583 672**  
[awilliams@emyria.com](mailto:awilliams@emyria.com)

**Sufian Ahmad**  
**Corporate Advisor**  
**+61 (0) 412 316 162**  
[info@62capital.com.au](mailto:info@62capital.com.au)

### DRUG DEVELOPMENT

**CLINICAL PROGRAMS**  
Ultra-Pure cannabinoid delivery platform

### NEW DRUG DISCOVERY

**PRE-CLINICAL PROGRAM**  
MDMA-like analogues

EMD-RX5 "direct-to-consumer"	
Formulation optimisation	✓
Phase 1 study	✓
Ethics approved for Phase 3	✓
Phase 3 commencement	✓
Regulatory submission	
Commercial strategy <b>Australia</b>	
Commercial strategy <b>Europe</b>	
Commercial strategy <b>USA</b>	

EMD-RX7 "prescription medicine"	
Formulation optimisation	✓
Phase 1	
Pre-IND (FDA)	
Pivotal trials	

MDMA-like drug development	
Continuous creation & screening	✓
First patent family filed	✓
US-focussed preclinical program	✓
Metabolic studies	✓
Preclinical assays (multiple animal models)	✓
Human cell line assays	✓
Advanced assay development	
Lead selection	
Phase 1 trials	
Global commercial strategy	

## ABOUT EMYRIA | [emyria.com](https://emyria.com)

**Emyria Limited** is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

#### EMYRIA'S

[Investorhub.emyria.com](https://investorhub.emyria.com)

#### INTERACTIVE

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

#### INVESTOR

#### HUB

**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.